Abstract
Dysmenorrhea is a prevalent and recurrent gynaecological disorder characterised by menstrual pain arising from inflammatory, neuroendocrine, and functional mechanisms, often inadequately managed by long-term conventional therapies. Ayurveda conceptualises this condition as Udavartini Yonivyapad, attributed to vitiation and disordered movement of Apana Vata, providing a functional framework for holistic management. This review aims to critically examine primary dysmenorrhea from both biomedical and Ayurvedic perspectives and to evaluate the therapeutic relevance of Ksheerapaka, with particular emphasis on the rationale for developing a dried powder formulation to enhance clinical applicability. A narrative review was conducted using peer-reviewed literature retrieved from PubMed and Scopus, published between 2015 and 2025, focusing on dysmenorrhea, Ksheerapaka, milk-based Ayurvedic formulations, and pharmaceutical dosage form innovations. Evidence from clinical, experimental, and observational studies indicates that Ksheerapaka exhibits analgesic, anti-inflammatory, Vata-pacifying, and tissue-nourishing properties, with consistent benefits reported in gynaecological and pain-related conditions; however, dysmenorrhea-specific clinical evidence remains limited. The review identifies key pharmaceutical challenges associated with the classical liquid formulation, including limited stability, dosing variability, and reduced patient adherence. Reformulation into a dried powder form is highlighted as a scientifically sound strategy to improve shelf life, standardisation, dosing precision, and usability, while preserving therapeutic intent. The review concludes that dried powder Ksheerapaka represents a promising integrative approach for primary dysmenorrhea management, but systematic formulation development and targeted clinical evaluation are needed to support evidence-based adoption.